scholarly journals Risk Factors, Treatment and Prognosis of Patients with Lung Cancer after Heart Transplantation

Life ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 1344
Author(s):  
Karsten M. Heil ◽  
Matthias Helmschrott ◽  
Fabrice F. Darche ◽  
Tom Bruckner ◽  
Philipp Ehlermann ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Heart Transplantation ◽  
Smoking Status ◽  
Lung Cancer Screening ◽  
Immunosuppressive Drugs ◽  
Term Survival ◽  
Lung Cancer Patients ◽  
Post Transplant ◽  
Diagnosis Of Lung Cancer

Long-term survival after heart transplantation (HTX) is impacted by adverse effects of immunosuppressive pharmacotherapy, and post-transplant lung cancer is a common occurrence. This study aimed to examine the risk factors, treatment, and prognosis of patients with post-transplant lung cancer. We included 625 adult patients who received HTX at Heidelberg Heart Center between 1989 and 2018. Patients were stratified by diagnosis and staging of lung cancer after HTX. Analysis comprised donor and recipient characteristics, medications including immunosuppressive drugs, and survival after diagnosis of lung cancer. A total of 41 patients (6.6%) were diagnosed with lung cancer after HTX, 13 patients received curative care and 28 patients had palliative care. Mean time from HTX until diagnosis of lung cancer was 8.6 ± 4.0 years and 1.8 ± 2.7 years from diagnosis of lung cancer until last follow-up. Twenty-four patients (58.5%) were switched to an mTOR-inhibitor after diagnosis of lung cancer. Multivariate analysis showed recipient age (HR: 1.05; CI: 1.01–1.10; p = 0.02), COPD (HR: 3.72; CI: 1.88–7.37; p < 0.01), and history of smoking (HR: 20.39; CI: 2.73–152.13; p < 0.01) as risk factors for post-transplant lung cancer. Patients in stages I and II had a significantly better 1-year (100.0% versus 3.6%), 2-year (69.2% versus 0.0%), and 5-year survival (53.8% versus 0.0%) than patients in stages III and IV (p < 0.01). Given the poor prognosis of late-stage post-transplant lung cancer, routine reassessment of current smoking status, providing smoking cessation support, and intensified lung cancer screening in high-risk HTX recipients are advisable.

scholarly journals PROSPECTS FOR THE APPLICATION OF THE MOST MODERN METHODS OF DIAGNOSIS OF LUNG CANCER

2019 ◽  
pp. 3-7
Author(s):  
I. О. Vynnychenko ◽  
Yu. V. Moskalenko ◽  
O. І. Vynnychenko ◽  
M. Yu. Serdyuk ◽  
O. А. Ternovenko
Keyword(s):  
Lung Cancer ◽  
Lung Cancer Screening ◽  
Human Lung Cancer ◽  
Endobronchial Ultrasound ◽  
Lung Cancer Patients ◽  
Current State ◽  
Modern Methods ◽  
Screening Sensitivity ◽  
Diagnosis Of Lung Cancer

Lung cancer is one of the major causes of death from malignancies. That is why the article devoted to the issue early diagnosis of lung cancer. The objective of the work is to consider the features and prospects of using the most modern methods of diagnosis of lung cancer. The introduction of the latest technologies is essential for quality screening of lung cancer patients. Gradually, there is a growing interest in developing strategies around the world to better assess the risk of human lung cancer, increase screening sensitivity, and reduce costs. The methods of early detection of lung cancer are described in the article: determination of the concentration of volatile organic compounds (LuCID method), endobronchial ultrasound (EBUS method), FISH-marker method, basic principles of the Nano-Nose device. Despite some advances in our country in the diagnosis of lung cancer using common advanced methods of computed tomography and biopsy, the introduction of foreign experience in lung cancer screening is necessary, because the current state-of-the-art methods of diagnosis allow to detect cancer.

Paediatric heart transplantation: an update

2019 ◽  
Vol 104 (12) ◽  
pp. 1216-1222
Author(s):  
Zdenka Reinhardt
Keyword(s):  
Heart Transplantation ◽  
Organ Procurement ◽  
Surgical Techniques ◽  
Immunosuppressive Drugs ◽  
Lymphoproliferative Disease ◽  
Current Status ◽  
Term Survival ◽  
Post Transplant ◽  
Monitoring Strategies ◽  
End Stage

Heart transplantation is a standard treatment for selected paediatric patients with end-stage heart disease. With improvement in surgical techniques, organ procurement and preservation strategies, immunosuppressive drugs, and more sophisticated monitoring strategies, survival following transplantation has increased over time. However, rejection, infection, renal failure, post-transplant lymphoproliferative disease and post-transplant cardiac allograft vasculopathy still preclude long-term survival. Therefore, continued multidisciplinary scientific efforts are needed for future gains. This review focuses on the current status, outcomes and ongoing challenges including patient selection, indications and contraindications, national and international survivals, post-transplant complications and quality of life.

scholarly journals Risk factors for postoperative complications and long-term survival in lung cancer patients older than 80 years†

2017 ◽  
Vol 53 (5) ◽  
pp. 980-986 ◽  
Author(s):  
Haruaki Hino ◽  
Takahiro Karasaki ◽  
Yukihiro Yoshida ◽  
Takeshi Fukami ◽  
Atsushi Sano ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Postoperative Complications ◽  
Cancer Patients ◽  
Term Survival ◽  
Long Term Survival ◽  
Lung Cancer Patients

scholarly journals Analysis of the Clinicopathological Characteristics and Risk Factors in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Jian-Long Miao ◽  
Jing-Jing Cai ◽  
Xiao-Feng Qin ◽  
Rui-Juan Liu
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Smoking Status ◽  
Clinicopathological Characteristics ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Lung Cancer Patients ◽  
High Risk Factors ◽  
Male Sex

Objective. To investigate the clinicopathological characteristics and risk factors in patients with lung cancer and COPD. Materials and Methods. We retrospectively reviewed the clinical data of 282 patients with lung cancer, including 174 and 108 patients with and without COPD, respectively. Information on age, sex, smoking status, and histologic type was obtained from medical records. Results. Lung cancer patients with COPD and those with the chronic bronchitis (CB) phenotype had higher smoking indices compared to those without COPD (723.95±631.48 and 920.95±712.93 versus 418.40±506.84; P=0.010; P=0.001, resp.), and current smokers accounted for significantly higher proportions of lung cancer patients with COPD and the CB phenotype versus without COPD (51.15% and 63.74% versus 35.19%; P=0.009; P=0.001, resp.). Adenocarcinoma was significantly more common in lung cancer patients without versus with COPD (48.15% versus 35.63%; P=0.037), whereas small cell lung cancer was more common in patients with COPD (23.56% versus 13.89%). Among patients with COPD, male sex (odds ratio [OR], 19.946; P<0.001), current smokers (OR: 6.588; P=0.001), and age ≥ 75 years (OR: 2.670; P=0.008) were identified as high-risk factors. Conclusion. The risk factors for COPD among lung cancer patients were age ≥ 75 years, current smokers with the CB phenotype, and male sex.

Detection of FHIT and p16 mRNA Deletion in Biopsy Specimens Obtained by Bronchoscopy for the Diagnosis of Lung Cancer

2013 ◽  
Vol 28 (3) ◽  
pp. 259-266 ◽  
Author(s):  
Ping Chen ◽  
Jian Li ◽  
Yi Wang ◽  
Li-Rong Zhu ◽  
Yi-Ming Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Smoking Status ◽  
Diagnostic Value ◽  
Gene Transcript ◽  
Detection Rates ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

The purpose of this study was to investigate the diagnostic value of the deletion of fragile histidine triad (FHIT) and p16INK4a (p16) mRNA in biopsies obtained by bronchoscopy. Biopsies were analyzed using RT-PCR in 52 patients with lung cancer and 19 patients with benign lung disease. The results showed that the detection rates of FHIT and p16 gene transcript deletion were significantly higher in lung cancer patients than in patients with benign lung disease (65.4% versus 10.5%, p=0.001 and 59.6% versus 5.3%, p<0.001, respectively). The sensitivities for detecting FHIT and p16 transcript deletion in biopsies were 65.4% and 59.6% (combined 80.8%), respectively, which were markedly better than those of histology and cytology (42.3% and 34.6%, respectively; combined 57.7%). In 22 lung cancer patients with negative histology and cytology at initial bronchoscopy, FHIT and p16 mRNA loss was detected in 40.9% (9/22) and 36.4% (8/22) cases, respectively. FHIT mRNA loss was associated with smoking status in lung cancer patients. In conclusion, deletion of FHIT and p16 mRNA can be identified in biopsies obtained during bronchoscopic procedures. FHIT and p16 mRNA deletion can be used as biomarkers in the clinical diagnosis of lung cancer and may serve as adjuncts to histology and cytology in lung cancer diagnosis.

Long-term Survival and Risk Factors for Recurrence in Stage I Non-small Cell Lung Cancer Patients With Tumors up to 3 cm in Maximum Dimension

CHEST Journal ◽  
2010 ◽  
Vol 138 (2) ◽  
pp. 357-362 ◽  
Author(s):  
Ryo Maeda ◽  
Junji Yoshida ◽  
Genichiro Ishii ◽  
Tomoyuki Hishida ◽  
Keiju Aokage ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
Maximum Dimension ◽  
Term Survival ◽  
Lung Cancer Patients ◽  
Risk Factors For Recurrence

scholarly journals The homogeneous and heterogeneous risk factors for occurrence and prognosis in lung cancer patients with bone metastasis

2019 ◽  
Vol 17 ◽  
pp. 100251 ◽  
Author(s):  
Ben Wang ◽  
Lijie Chen ◽  
Chongan Huang ◽  
Jialiang Lin ◽  
Xiangxiang Pan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Bone Metastasis ◽  
Cancer Patients ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document